

IMPACT REPORT

JANUARY - DECEMBER 2021

PLEASE NOTE CURE4CF HAS MOVED TO A
CALENDAR YEAR FINANCIAL REPORTING
PERIOD FOR 2021.

CURE4
CYSTIC
FIBROSIS



CONTENTS

FROM OUR CHAIR	4
FROM OUR EXECUTIVE MANAGER	7
ABOUT CURE4CF	9
WHAT IS CYSTIC FIBROSIS	10
OUR BOARD	11
OUR TEAM	12
OUR AMBASSADORS	13
INDEPENDENT ADVISORY PANEL.....	14
OUR SUB-COMMITTEES.....	15
12 MONTH SNAPSHOT.....	17
OUR RESEARCH PROGRAM.....	18
HOLCKNER FAMILY CF IMPACT GRANT.....	19
MEET OUR NEW RESEARCHERS.....	20
OUR RESEARCH PARTNERS.....	22
COMMUNITY FUNDRAISING.....	27
D-DAY.....	34
OUR PARNTERS.....	36
JOIN THE FIGHT.....	37
ACKNOWLEDGEMENTS	38
FINANCIALS	40

**“CURE4CF ONLY FUNDS
CF RESEARCH.
AND WE ONLY FUND THE
TYPE OF RESEARCH
THAT HAS THE BEST
CHANCE OF MAKING IT
INTO THE HANDS OF
THOSE WHO NEED IT
MOST”**

CURE4 CYSTIC FIBROSIS FOUNDATION

FROM OUR CHAIR

LACHLAN MONFRIES



We are incredibly proud to once again be reflecting on a year where we have well and truly fulfilled our purpose of uniting our community to

accelerate Australia's best research towards a global cure for cystic fibrosis.

While the past two years have been challenging, it's a credit to our fundraisers, supporters, staff, volunteers, and board that we move into 2022 in a significantly stronger position than we entered the pandemic, where we will once again increase the level of funding that we contribute towards world leading translational research.

This is my first Chair's report since being appointed in October 2020. I have cystic fibrosis and understand the devastating impact it can have not just on CF Warriors but those around them. I'm incredibly driven to accelerate a cure for both the CF community and personally to ensure I maximise the time that I have with my son Harvey who is now 8 years old.

A huge thank you to outgoing Chair Jo Close for her tireless work and continued support as a Board and sub-committee member, and congratulations to Director Stephanie Morris who has been elevated to the role of Deputy Chair.

This year Cure4CF continued to expand its reach across the CF community. With community fundraisers and supporters

across all States & Territories in Australia, Cure4CF is a proud national foundation.

This is made possible thanks to our supporters who make up our incredible Cure4CF Army. An army that helped raise and extraordinary \$891k despite ongoing headwinds due to Covid-19.

This year there have been many highlights, however a few standouts include the naming rights partnership with the Holckner family, who know first-hand the impact of cystic fibrosis. They joined forces with Cure4CF to accelerate the volume of research we can fund, and we are delighted to partner with them. The establishment of a CF specific Independent Advisory Panel which allows us to critically assess research opportunities and continue to maximise the impact of our donors' funds. The successful delivery of our D-Day fundraising event with matched donations from partners and the generosity of our community raised \$128k, an increase of 40% on the D-Day 2020. And awarding our inaugural Holckner Family CF Impact Grant to Professor Kevin Morris and Dr Gerard Kaiko. This saw Cure4CF grant \$500k towards their joint project to develop and test a novel gene therapy approach to treat cystic fibrosis.

Our research program has grown from strength to strength. With a clear purpose and pathway to a cure, we remain steadfast and committed to our goal – to see the research we fund translated into clinical benefit. We continue to focus on research that has the potential for those with CF to live a 'normal life'.

The most important priority is for a full lifetime. We're attacking cystic fibrosis from many angles and our research partnerships reflect our approach of building a portfolio of projects that have the potential to transform cystic fibrosis globally. I hope you will take the time to learn more about the novel gene therapy approach that Prof Morris and Dr Kaiko are taking outlined in this report. It certainly is an exciting time in the cystic fibrosis research space, and we have much to hope for.

I was delighted with the addition of three new Board members with diverse skillsets to complement the existing Board. Dr Steven Zadow joins us with over 20 years as a radiologist and partner for Dr Jones and Partners Medical Imaging, and is father to a CF Warrior. In his early career he was involved in Respiratory Medicine research and management of patients with cystic fibrosis. He is now a medical specialist radiologist with a diverse skillset including strong commercial acumen as well as research and clinical experience. Dr Phil Kearney, an accomplished scientist and health technology expert, brings extensive international research experience having joined Merck Sharp and Dohme Australia in 2007 as the key scout for innovative research and development in Australia, New Zealand, India, and some parts of Southeast Asia. In his time with MSD, he transacted deals worth more than \$2B, covering acquisition, licenses, and research and development collaborations with biotech's and academic institutions. And Dr Matt Chong, another scientist who brings significant experience in research translation, commercialisation and grant funding having worked in the life sciences industry for over 20 years. Matt is a Client Engagement Facilitator at the Australian National Fabrication Facility and has

worked for the SA government and several Australian universities, which has given him great experience in all aspects of the research funding lifecycle.

We also welcomed Birgit Smith, who joined the organisation as Fundraising and Operations Coordinator with a strong background in membership, marketing, and communications.

I would like to thank everyone who contributed to the organisation's success in 2021 with special recognition to our Executive Manager Suzy Dimaline whose passion to make a difference and support the CF community is incredible, her agility and resilience in 2021 was remarkable and the results are testament to her hard work. We couldn't have the impact we do without the support of our ambassadors, a group of dedicated, hard-working people who continually hero our cause and advocate for us within the CF community. Special thanks to the generous members of our Heroes League who seek to make the biggest impact they can through their personal contributions, connections and by championing our cause.

We welcomed our first Patron Greg Oke, who as the proud founder of Cure4CF continues to contribute to the organisation and provide strategic guidance to the Board and staff.

My heartfelt thanks to Greg Knagge and the team at Nation who continued to help tell the story of Cure4CF and connect us to our CF community.

Thanks to Kayi Li for providing incredible support and guidance as Treasurer to assist us to manage our way through a challenging COVID environment. Kayi

has retired as a Director as she starts her family.

Finally, thank you to the Board for being inspired by our purpose and contributing their unique skillsets, passion and time towards accelerating a cure for cystic fibrosis.

I'm so excited for what 2022 will bring. The organisation is in a fantastic position to continue to grow and connect with the CF community, which will significantly increase the impact we make towards accelerating a cure.

I look forward to sharing our progress as we go through the year.



LACHLAN MONFRIES - CURE4 CYSTIC FIBROSIS CHAIR

FROM OUR EXECUTIVE MANAGER

SUZY DIMALINE



Thanks to our Army of supporters, Cure4CF has had a very successful year. One of the ways we measure our success is by the volume and quality of research we

fund. Our priority is to fund research that will bring about therapies and cures for people with cystic fibrosis. Research that builds on existing knowledge and has a clearly identified path and a commitment for translational impact. Thanks to our annual Holckner Family CF Impact grant we have done just that and uncovered a novel gene therapy project that aims to develop a clever zinc finger. I couldn't be more excited to welcome Prof Kevin Morris and Dr Gerard Kaiko as our 2021 research partners. You can read more about their exciting work in this Impact Report.

Despite the ongoing global challenges that continue to impact the way we raise funds, we were able to grant \$500,000 for CF research. This is an incredible achievement in a tough landscape, and we could only do this because of the remarkable people who support our cause. An army of special people who see the injustice of CF and rolled up their sleeves and took action.

They are the reason we can continue our important work.

We are fortunate to work with incredible Ambassadors who use their voices and platforms to bring attention to our cause and help increase the volume of research we can invest in. Their substantial hours of voluntary service enabled us to keep our

overheads low and our impact great. The value they bring to the Foundation is immeasurable and we're so grateful to work alongside such talented and passionate people.

Our Community Fundraisers once again played an instrumental role raising funds and awareness for our cause. We welcomed many new fundraisers and celebrated those who held their annual events. Their battle cries were heard right across Australia and despite the ongoing challenges and restrictions to gatherings, they found smart COVID friendly ways to raise more than \$180K for CF research. A truly outstanding effort in challenging times.

Our quest for a cure would not be possible without our partners. It is their action that has seen Cure4CF grow from strength to strength and it's in partnership with them that we can achieve more. Thank you to the Holckner family who joined us this year as a Naming Rights Partner for our annual research grant with a three-year commitment. I look forward to uncovering more excellent research in partnership with them.

I'd also like to thank the CMV Foundation who for the last three years have supported our Community Ambassador program. Their funding of this innovative program has seen us increase our capacity through voluntary hours and add skills and experience that has strengthened our Foundation. You can read more about all our amazing partners, who are highlighted further in this impact report.

A special mention to Greg Knagge and his talented team at Nation who continued to provide excellent creative and strategic direction this year. The contribution Nation has made in providing ongoing pro bono marketing and communication support has been significant. We consider Nation to be part of our organisation in that the team understand our goals and are as passionate as our team about achieving them. It is a true collaborative partnership that we are very grateful for.

It's been an extremely busy and productive year filled with many achievements, none of which would have happened without the commitment and hard work of a skilled team. My sincere thanks to Jessica Buckley, who made the hard decision to move on to a new challenge with the Childhood Cancer Association as their Fundraising Manager. She played a major role in shaping Cure4CF into the national Foundation it is today, and we cannot thank her enough for her dedication and hard work over the past 3.5 years. While we will miss her, we are excited for her as she embarks on a new career.

We eagerly welcomed Birgit Smith to our team in June. Her experience in marketing and membership management was a welcome addition and her warm nature and kind spirit saw her quickly become one of the Cure4CF family. She hit the ground running and has continued to show her dedication to our fight.

With just two paid employees, our voluntary sub-committees ensure we have all the skills needed to run a successful Foundation. I am lucky to be surrounded by some of the brightest minds across

Australia, who bring expert knowledge and experience to our team. Their involvement is priceless, and I am grateful for the important contributions they are making.

My thanks to new Chair, Lachlan Monfries for embracing the role so passionately and providing important insights as a leader and CF Warrior, and to former Chair and current Director Jo Close, for her continued mentorship and hard work. Thank you to the Board for another year of active service. Their considerable contributions continue to strengthen our Foundation.

Finally, to our Researchers, CF community, donors, and Heroes League members, it is with my deepest gratitude I highlight the crucial role they have played this year. Cure4CF is their Foundation, it simply wouldn't exist without them. They are the key to a cure and with their backing and their faith in our work, there is nothing that we cannot achieve, it is just a matter of time.



SUZY DIMALINE- EXECUTIVE MANAGER

OUR CORE VALUES

INTEGRITY

WE REMAIN
UNCOMMONLY
ACCOUNTABLE AND
TRANSPARENT WHEN IT
COMES TO OUR GOALS
AND OPERATIONS.

ABOUT CURE4CF

CURE4 CYSTIC FIBROSIS FOUNDATION

Cure4CF was formally established in 2007 and is a registered not-for-profit organisation with a vision for a cure for cystic fibrosis. Cure4CF furthers this mission by raising funds across the country and directing them to support promising Australian medical research; research that has the best chance of making it into the hands of people with CF.

OUR DIFFERENCE

We exclusively fund research into therapies and treatments that will either cure CF or significantly extend the life expectancy of people living with CF. This is our key point of difference.

Cure4CF is Australia's largest private funder of CF research. We raise funds through community fundraising, major gifts, sponsorships and grants. To date, in partnership with our community we have raised over \$5M to invest in a cure for CF.

OUR FUNDING MODEL

We have a rigorous model for our funding, with excellent governance and reporting frameworks supported by an expert Advisory Committee. Our grants process ensures our focus is on funding translational research – that has scientific, clinical and commercial merit and a focused pathway to clinical outcomes.

Our goal is to see the research we support translated into clinical benefit - and we emphasise this from the very beginning, prioritising projects that have a clear translational path and researchers who are committed to taking the necessary steps to see their innovation in the hands of patients.

OUR IMPACT

Through our recent grant round, we have uncovered incredible Australian research that has the potential to transform CF treatment globally. Through targeted funding, we can accelerate this research.

OUR PEOPLE

We are a small team of just 2 FTE staff and a dynamic Board of 9 Directors. We run a lean organisation to keep our overheads low, but our impact is great. We want to make every dollar raised count. Our volunteer strategies, such as our highly engaged Board and Ambassadors, are key to achieve this.

WHAT IS CYSTIC FIBROSIS

CYSTIC FIBROSIS IS THE MOST COMMON LIFE LIMITING GENETIC DISORDER AFFECTING AUSTRALIANS TODAY. IT MAINLY AFFECTS THE LUNGS, THE DIGESTIVE SYSTEM, AND THE REPRODUCTIVE SYSTEM.

Cystic fibrosis (CF) is a complex disease and the types and severity of symptoms can differ widely from person to person.

CF is a disease that affects the cells that produce mucus, sweat and digestive juices. These fluids are normally thin and slippery. But in people with CF, a defective gene causes the secretions to become sticky and thick. Instead of acting as lubricants, the secretions plug up tubes, ducts and passageways, especially in the lungs and pancreas.

MANIFESTATIONS OF CF

GENERAL
GROWTH FAILURE (MALABSORPTION)
VITAMIN DEFICIENCY STATES (VITAMINS A, D, E, K)


NOSE AND SINUSES
NASAL POLYPS
SINUSITIS

LIVER
HEPATIC STEATOSIS
PORTAL HYPERTENSION

GALLBLADDER
BILIARY CIRRHOSIS
NEONATAL OBSTRUCTIVE JAUNDICE
CHOLELITHIASIS

BONE
HYPERTONIC OSTEODYSTROPHY
CLUBBING
ARTHRITIS
OSTEOPOROSIS

INTESTINES
MECONIUM ILEUS
MECONIUM PERITONITIS
RECTAL PROLAPSE
INTUSSUSCEPTION
VOLVULUS
FIBROSING COLONOPATHY (STRICTURES)
APPENDICITIS
INTESTINAL ATRESIA
DISTAL INTESTINAL OBSTRUCTION SYNDROME
INGUINAL HERNIA



LUNGS
BRONCHIECTASIS
BRONCHITIS
BRONCHOLITIS
PNEUMONIA
ATELECTASIS
HEMOPTYSIS
PNEUMOTHORAX
REACTIVE AIRWAY DISEASE
COR PULMONALE
RESPIRATORY FAILURE
MUCOID IMPACTION OF THE BRONCHI
ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS

HEART
RIGHT VENTRICULAR HYPERTROPHY
PULMONARY ARTERY DILATION

SPLEEN
HYPERSPLENISM

STOMACH
GERD

PANCREAS
PANCREATITIS
INSULIN DEFICIENCY
SYMPTOMATIC HYPERGLYCEMIA
DIABETES

REPRODUCTIVE
INFERTILITY (ASPERMIA,
ABSENCE OF VAS DEFERENS)
AMENORRHEA
DELAYED PUBERTY

In the lungs, the mucus clogs the airways and traps germs, like bacteria, leading to infections, inflammation, respiratory failure, and other complications. For this reason, minimising contact with germs is a major concern for people with CF.

In the pancreas, the build-up of mucus prevents the release of digestive enzymes that help the body absorb food and key nutrients, resulting in malnutrition and poor growth. In the liver, the thick mucus can block the bile duct, causing liver disease.

One in 25 Australians are carriers of the defective gene that causes CF and currently there is no cure.

The average lifespan of a person with CF is around 38 years, but there is reason to hope. With ongoing improvement of modular drugs such as Orkambi and Trikafta and increased investment in CF research across the globe, there is a united effort to find a cure.

OUR BOARD & PATRON

WE FIGHT BECAUSE WE NEED A CURE FOR CYSTIC FIBROSIS AND RESEARCH IS THE ANSWER.



LACHLAN MONFRIES - CHAIRMAN



STEPHANIE MORRIS -DEPUTY CHAIR



JO CLOSE - DIRECTOR



JENNA DIKIH - TREASURER




PHIL KEARNEY - DIRECTOR



CLINTON JURY - DIRECTOR



GREG SAVAGE - DIRECTOR



KAYI LI - DIRECTOR



MATTHEW CHONG - DIRECTOR



STEVEN ZADOW - DIRECTOR



GREG OKE - FOUNDER & PATRON

OUR TEAM

WE FIGHT IN PARTNERSHIP WITH THE CYSTIC FIBROSIS COMMUNITY TO ADVANCE A CURE.



**SUZY DIMALINE - EXECUTIVE
MANAGER**

Suzy has over 25 years' experience in the not-for-profit industry, particularly within the disability and employment sectors. She has lent her expertise to roles with the MS Society of SA & NT, Women's & Children's Hospital Foundation and the Art Gallery of South Australia. Suzy is an experienced multi-channel fundraiser, who specialises in driving income generation, donor development, stakeholder engagement and managing teams. Suzy is proud to lead an organisation with such a strong sense of purpose and clarity, and fights in partnership with the cystic fibrosis community to advance a cure.

Jessica is an experienced fundraiser, having worked for over 10 years' in the not-for-profit industry in both Australia and the UK. She has worked for Women's & Children's Hospital Foundation, PriceWaterhouseCoopers, LLP and the University of Adelaide. Jessica specialises in database management, data analysis and donor engagement, and is solutions focused with a strong analytical mind. As a carrier of the CF gene, Jessica fights to help find a cure for cystic fibrosis, a cause close to her heart having grown up with a friend with cystic fibrosis and seeing the effects it has on individuals and their families.



**JESSICA BUCKLEY- DONOR
DEVELOPMENT MANAGER**



**BIRGIT SMITH - FUNDRAISING
& OPERATIONS COORDINATOR**


Birgit brings a wealth of knowledge and experience having worked for over 10 years' in marketing and membership management. Specialising in developing and managing partnerships and running national marketing and communications campaigns, Birgit is a driven individual, passionate about the power of communications. She is excited to work alongside our CF community and looks forward to raising our collective voice in the fight against cystic fibrosis.

OUR AMBASSADORS

WE FIGHT BECAUSE OUR LIVES AND THAT OF OUR LOVED ONES DEPEND ON IT.



ANGUS MONFRIES - FORMER PT
ADELAIDE PLAYER & BROTHER TO CF
WARRIOR LACHIE



EMMAH MONEY - CF MUMMY &
CF WARRIOR



JAMES KOZLOWSKI - CURE4CF
COMMUNITY AMBASSADOR FOR
NSW & UNCLE TO CF WARRIOR
AVELINE



JAMIE SACH - PENFOLDS GLOBAL
AMBASSADOR & DAD TO CF WARRIOR
OTTO




KRISTY THOMAS - CURE4CF
COMMUNITY AMBASSADOR FOR QLD
& MUM TO CF WARRIOR LEO




LEANN TREMUL - CURE4CF
COMMUNITY AMBASSADOR FOR
VIC & MUM TO CF WARRIOR GABBY



MAE JOHNSON - CURE4CF YOUTH
AMBASSADOR & CF WARRIOR



MELLY HAYNES - CURE4CF
AMBASSADOR & CF WARRIOR



OLIVIA WOOD - CURE4CF COMMUNITY
AMBASSADOR FOR NSW & CF
WARRIOR

INDEPENDENT ADVISORY PANEL

CURE4CF ENGAGES THE VOLUNTARY SERVICES OF AN EXPERT INDEPENDENT ADVISORY PANEL TO HELP DETERMINE THE BEST RESEARCH TO FUND ACROSS AUSTRALIA.

Cure4CF receives advice and recommendations from an Independent Advisory Panel (IAP). Its role is to evaluate and support innovative and high-quality research projects with a clear impact. These services are provided at no charge to Cure4 Cystic Fibrosis.



DR HELGA MIKKELSEN -
INVESTMENT ANALYST BRANDON
CAPITAL



DR SIOBHAIN MULRENNAN -
CLINICAL PROFESSOR UWA



KRISTY THOMAS -
CF PARENT REPRESENTATIVE



DR STEPHEN THOMPSON -
MANAGING DIRECTOR BRANDON
CAPITAL



PROF STEVE WESSELINGH -
EXECUTIVE DIRECTOR SAHMRI

OUR SUB-COMMITTEES

WE RUN A LEAN ORGANISATION TO KEEP OUR OVERHEADS LOW AND OUR IMPACT GREAT. WE WANT TO MAKE EVERY DOLLAR RAISED COUNT. OUR VOLUNTEER STRATEGIES, SUCH AS OUR HIGHLY ENGAGED SUB-COMMITTEES, ARE KEY TO ACHIEVE THIS.

In addition to our Executive Manager who sits on all committees, the following people help increase the capacity, productivity and impact of our Foundation.

RESEARCH & COMMERCIALISATION



STEPHANIE MORRIS -
CHAIR



JO CLOSE



NICOLETTE HODYL



PHIL KEARNEY



MATTHEW CHONG

GOVERNANCE



JENNA DIKIH - CHAIR



LACHLAN MONFRIES



GREG SAVAGE



CLINTON JURY



STEVEN ZADOW

BRAND & FUNDRAISING



LACHLAN MONFRIES -
CHAIR



GREG KNAGGE - NATION



TOM BENSON - NATION



BIRGIT SMITH



SUZY DIMALINE

OUR CORE VALUES

INSPIRATION

**WE SPREAD THE POWER
OF OPTIMISM WITH A
RELENTLESSLY WARM
SPIRIT.**

12 MONTH SNAPSHOT

\$891,821

**TOTAL DONATIONS AND GRANTS
RECEIVED**



1,923

GIFTS RECEIVED



1,246

DONORS GAVE



927

NEW DONORS



2

**NEW RESEARCH
PROJECTS FUNDED**

\$500K

**FUNDS AWARDED TO
NEW PROJECTS**



\$250K

FUNDS PAID OUT

OUR RESEARCH PROGRAM

WE ARE FOCUSED ON RESEARCH THAT HAS THE POTENTIAL FOR OUR CF WARRIORS TO LIVE A 'NORMAL LIFE'. THE MOST IMPORTANT PRIORITY IS FOR A FULL LIFETIME.

Since 2007 Cure4CF has solely funded cystic fibrosis research with a focus on a cure. We do this by funding innovative research that builds on existing knowledge and has a clearly defined path and a commitment for translational impact.

Our goal is to see the research that we support translated into clinical benefit - and we emphasise this from the very beginning, prioritising projects that have a clear translational path and researchers who are committed to taking the necessary steps to see their innovation in the hands of patients.

This means we don't fund basic or fundamental research. We support research programs where theories have been demonstrated, scientific curiosity satisfied and where practical utility is evident. We expect the funding we provide will add commercial value to discoveries and result in therapeutic candidates progressing along the translation pathway.

It also means we work with our funding recipients to support them in their next stages of translation - whether that be connecting to the next funding source, providing commercialisation advice or assisting with translation into clinical guidelines.

Technology Readiness Levels

1	Exploratory / Basic Scientific Principles Observed
2	Application of Scientific Principles Hypothesised
3	Experimental Proof of Concept
4	Validation in Laboratory Environment (e.g. cellular assays)
5	Validation in Relevant Simulated Environment (e.g. animal models)
6	Preparation for Field Studies (e.g. safety, product scale-up)
7	Initial Proof of Concept in Field (e.g. phase I/II clinical studies)
8	Proof of Concept in Field (e.g. phase III clinical studies)
9	Regulatory Approval & Launch

Research Types

We support	Therapeutics, Cell & Gene Therapies, Antimicrobials, Vaccines
We don't support	Diagnostics, Devices, Observational, Epidemiology

HOLCKNER FAMILY CF IMPACT GRANT 2021-2023

THIS YEAR WE WERE DELIGHTED TO WELCOME THE HOLCKNER FAMILY TO OUR CURE4CF ARMY AS NAMING RIGHTS SPONSORS OF THE CURE4CF ANNUAL RESEARCH GRANT.



Mark Holckner, Helen Landau, Anne Melinger, David Holckner
Charles Holckner OAM (seated in front).
(Image in background features Charles Holckner and his late wife Lily Holckner)

The Holckner family know first hand the impact of cystic fibrosis and are taking the necessary action to help accelerate Australia's best research towards a global cure for cystic fibrosis.

'The Holckner family are proud to support and be associated with Cure4CF and specifically the naming of the annual Holckner Family Cure4CF Research Grant.

A 3rd generation Australian born member of the Holckner family, Jarrod, has lived with Cystic Fibrosis for over 45 years.

We hope that our contribution and support for the grant will find solutions for those like Jarrod who live with CF and improve their quality of life.'

MEET OUR NEW RESEARCHERS

THROUGH OUR 2021 HOLCKNER FAMILY CF IMPACT GRANT WE HAVE UNCOVERED INCREDIBLE AUSTRALIAN RESEARCH WITH THE POTENTIAL TO CURE CYSTIC FIBROSIS.


Professor Kevin Morris and Dr Gerard Kaiko have joined forces on this national project to develop and test a novel gene therapy approach to treat cystic fibrosis. Their project will:

- (1) Further develop a clever zinc finger, which makes cells produce more CFTR protein; and
- (2) See if they can engineer the liver to become a factory that produces the zinc finger.

This is exciting because it combines the latest scientific discoveries from across the globe in gene therapy and stem cells. It offers the potential to treat the majority of CF mutations, including rare mutations, and would also be used to enhance existing therapies like Trikafta. If successful, the outcomes of this research could ultimately lead to a treatment that has a long-term or permanent effect on the whole body, not just the lungs.

Kevin is an enthusiastic surfer from California, who also happens to be a world leading gene therapy researcher. He's globally recognised in his field for major discoveries that have shifted scientific understanding of how genes produce proteins – essential for understanding genetic conditions like cystic fibrosis. He was first to discover how an important molecule was involved in 'switching on' the main CF gene.

Griffith University in Queensland has been home for the Morris laboratory for two years, and the team maintains close collaborations nationally and internationally, particularly in the United States.



MEET OUR NEW RESEARCHERS CONT...

Gerard is passionate about improving lives for those with chronic diseases like cystic fibrosis. He has an accomplished international scientific career in respiratory diseases and immunology, which led him back to Australia to establish an expert capability in lung stem cells at Hunter Medical Research Institute in Newcastle – their respiratory centre is one of the best in the world.

CFTR

Cystic fibrosis is the result of a particular protein, the cystic fibrosis transmembrane conductance regulator (CFTR) protein, not functioning well or at all. The CFTR protein sits on the outside of cells and maintains the balance of salt and water. Malfunctional CFTR protein leads to mucus covering cells, which causes many of the symptoms associated with CF, particularly apparent in the lungs where bacteria harbour causing permanent damage.

A significant challenge in addressing CF is that there are many different kinds of problems with the CFTR protein: it might not be made by the cell; it may be made but for some reason doesn't reach the surface of the cell; it might get to the surface but it just doesn't work at all or the right way; there might not be enough CFTR proteins or they don't last when they reach the cell surface.

CFTR modulator drugs, like Trikafta, are CFTR protein “fixers” – they are molecules that interact with the CFTR protein to fix its shape or help it function at the cell surface. Each modulator has its own way of fixing and works with particular protein problems.

The limitation of CFTR modulators is that they require the CFTR protein to be made by the cell, and in sufficient quantities. They are also very specific in the way they “fix” and so can't fix every kind of malfunctioning CFTR protein.

This is where our innovative Zinc Finger has a significant role to play.

Read more about the science

Villamizar O, Waters SA, Scott T, Grepo N, Jaffe A, Morris KV. Mesenchymal Stem Cell exosome delivered Zinc Finger Protein activation of cystic fibrosistransmembrane conductance regulator. J Extracell Vesicles. 2021;10(3):e12053. Epub 2021/02/04. doi: 10.1002/jev2.12053. PubMed PMID: 33532041; PMCID: PMC7825549.

OUR RESEARCH PARTNERS

WE ARE BUILDING A PORTFOLIO OF RESEARCH THAT FIGHTS CYSTIC FIBROSIS ON MANY FRONTS.

DR LESZEK LISOWSKI

ALL-IN-ONE GENE THERAPY TREATMENT FOR CYSTIC FIBROSIS
CHILDREN'S MEDICAL RESEARCH INSTITUTE (CMRI) & THE UNIVERSITY OF SYDNEY


Dr Lisowski's project aims to develop new gene therapy tools for the treatment of CF.

His team will develop tools for safe and efficient targeting of the lung cells while specifically de-targeted from the human liver and use these to deliver a gene editing strategy to correct mutations in the fibrosis transmembrane conductance regulator (CFTR) gene.

The project experienced some delays in 2021 because of COVID restrictions but the team have worked to overcome this barrier and continue to progress well. With ethical approval for the project in place, they have developed a new collaboration with a team in Melbourne who will be able to provide the essential lung tissue for this project (milestone one).

Dr Lisowski's team have generated relevant vector libraries that will be used in the bioengineering process and have identified 8 candidates which are being processed and will be validated/tested in the next stages of the project.

The gene editing constructs have been validated in vitro and the next step will be to initiate in vivo evaluations.



OUR RESEARCH PARTNERS

PROF MARC PELLEGRINI

ERADICATING LIFE THREATENING INFECTIONS IN PEOPLE WITH CYSTIC FIBROSIS
WALTER & ELIZA HALL INSTITUTE OF MEDICAL RESEARCH VICTORIA

The team from WEHI led by Professor Marc Pellegrini have completed all milestones from their 2019/2020 project which established the efficacy of two compounds that can kill infected cells in animal and human immune cells, but leave uninfected and healthy cells intact.

They have shown that the same treatment is effective when used in conjunction with antibiotics and steroid therapy. This data supports the further assessment of these treatments in clinical trials and the team plan to seek funding for this work.

Prof Pellegrini has a PhD student travelling to Italy in May this year to continue the work and develop further international collaborations.

Cure4CF has funded two projects from Prof Pellegrini since 2019, the first project focused on the eradication of *Burkholderia cepacia*, and the second supported the team to expand their bacterial targets to include *Pseudomonas aeruginosa*. They plan to publish their complete work once the next stages have been finalised and hope to work with the Melbourne Children's hospital to further examine the treatment effects in human cells.



OUR RESEARCH PARTNERS

A/PROF SARAH VREUGDE

A NOVEL TREATMENT FOR NON-TUBERCULOUS MYCOBACTERIA LUNG INFECTIONS IN PEOPLE WITH CF
UNIVERSITY OF ADELAIDE

Associate Professor Sarah Vreugde received funding in 2020/2021 to pursue a promising treatment for nontuberculosis mycobacteria or NTM which is a growing problem for those with CF. Working with NTM requires much patience as the bacteria is very slow and difficult to grow in the laboratory and creating animal models to study the course of the infection and then its treatments has been challenging.

The team have a post-doctoral fellow working on this project and are collaborating with a pharmacologist to be able to package the treatment into a nanoparticle which can safely deliver the treatment to the airways.

Three milestones are now complete which include ethical approval for the use of a CF Rat model, safety studies for the CF rat model and important work to optimise the delivery method for this treatment. Current milestones include the work needed to establish the dosing for the treatment and further development of the rat model to adapt it for NTM infection. The next steps are to examine the treatment in an infection model and ultimately human cells.



OUR RESEARCH PARTNERS

PROF PJ WORMALD & A/PROF SARAH VREUGDE

PHAGE THERAPY

UNIVERSITY OF ADELAIDE

Professor Peter-John Wormald and Associate Professor Sarah Vreugde from the University of Adelaide's Faculty of Health and Medical Sciences will receive \$1,712,341 to fund a trial of a novel bacteria treatment to eradicate antibiotic-resistant infections in recalcitrant chronic rhinosinusitis (a chronic inflammatory condition of the upper airway) that affects nearly all cystic fibrosis patients.

'This is a great step in the direction of phage therapy for this condition in people with CF and was made possible thanks to seed funding by Cure4CF as well as other co-funding we received for this project.' said Associate Professor Vreugde. 'This study will be the first to provide evidence for the breakthrough potential of phage cocktails to eradicate these drug-resistant infections.'



OUR CORE VALUES

IMPACT

**WE WANT TO GIVE CYSTIC
FIBROSIS THE VISIBILITY
AND RESOURCES IT
NEEDS TO ACCELERATE A
CURE.**

OUR COMMUNITY FUNDRAISERS

OUR CF ARMY ONCE AGAIN DONNED THEIR WARRIOR STRIPES AND RAISED VITAL FUNDS FOR OUR RESEARCH PROGRAM.

Our CF army showed their might and raised \$180K by voting, walking, trekking, running, dancing, baking, partying, going casual, going without, wearing crazy hair, quizzing, drinking cocktails, drinking coffee, bowling, painting, watching movies, and via many other unique ways right across Australia.


Cystic fibrosis is a rare disease impacting just 3,500 Australians, and although our community may be small their voices are mighty and the action they took over the last 12 months brought us closer to a cure.

The funds raised enabled Cure4CF to make a commitment of funding up to \$500K in translational research this year through its annual grant round. Here are a few of the incredible people who supported Cure4CF in 2021.



MAE JOHNSON - INTRODUCING CURE4CF EVENT

Funded by the Westfield Local Hero's grant, Local Hero Mae and fellow Cure4CF Ambassador Jamie Sach hosted an 'Introduction to Cure4CF' evening, where guests were able to hear first-hand the good work of the Foundation, why we need a cure for cystic fibrosis and how they could help. The event raised a whopping \$33,000!



JAMES KOZLOWSKI & HIS ENDEAVOUR CURE4CF ARMY
Despite a few false starts due to COVID restrictions, this Cure4CF Army conquered 21km and raised an incredible \$30,750 for vital research.



CYCLING FOR CLAUDIA

Matt is heading to NZ in October to ride the Te Araroa track in memory of his girlfriend Claudia. So far he has raised a whopping \$22,645 for CF research.



SIOBHAN'S HAUNTED HOUSE

In support of her CF Warrior son, Siobhan put on a spooktacular display by decorating her home for Halloween and raised \$5,160 for research. What a truly outstanding effort!



CHARITY & FUN - JAN DALTON & JEN JURY

Faced with gathering restrictions, Jan and Jen turned their high tea into an at home experience with an online silent auction and raffle. They raised an incredible \$12,607.00!



EMMAH MONEY - COCKTAILS FOR A CURE

Emmah's unique idea of mixing cocktails and cure focused research paid off! She raised a fantastic \$8,500!





UNCLE ANDY ON A MISSION

Andy ran 5ks per day for 65 consecutive days and a further 675kms of walking and donated \$3,560 to Cure4CF. A brilliant effort!



THANK YOU!

THE KIND PROJECT - RAWAN ABDIN

One of Kind donated 10% of their sales during the month of August and raised \$1,000 for our research program. A great outcome!



CITY2SURF - TRUDY MULLIGAN

Running 14K in support of her CF Warrior niece, Trudy raised a brilliant \$2,240.



JESS GILL - BAKE SALE

In support of her CF Warrior brother, Jess and her team mates held a bake sale and raised \$720!



FLUID BUILDING APPROVALS

Our friends at Fluid chose Cure4CF as their charity of choice for the month of May and generously donated \$4,123!




TREK FOR JAKE

Montana completed his epic trek across New Zealand and raised an incredible \$26,000 in memory of his mate Jake Apps. A heroic effort indeed!



WENDY HARVEY - COOKIE FUNDRAISER

Wendy once again rolled up her baking sleeves and raised a fantastic \$1,400 in support of her CF Warrior grandson Leo.



JEN KOZLOWSKI - BAKING FUNDRAISER

Jen once again put her amazing talents to work and raised an incredible \$1,300 in support of her CF Warrior daughter Aveline.



BILLANOOK PRIMARY SCHOOL

held a casual day and raised \$100 for CF research!



THE GREAT ESCAPE OZ

After a couple of false starts over the past two years, the Great Escape OZ will finally kick off in late April 2022. The 7 day car rally through outback NSW and QLD has already raised \$4,175.



CAMERON MULLEN

Cameron ran the Nike Melbourne Marathon Festival in October and raised \$1,180!

CURE4CF DONATION DAY

D-DAY IS THE MOST POWERFUL DAY OF THE YEAR ON THE CURE4CF CALENDAR.




Following the success of our 2020 donation day, we once again rallied our community on December 3 and asked them to help raise funds in support of our research program. The response was overwhelming and together we raised an astonishing \$128,72! That equates to 1,950 hours of cure focused research by a senior scientist.

The introduction of this annual event and the way in which the community has embraced it, has substantially increased the volume of research we can support in any given year. To say we were blown away by this result is an understatement.

Thank you to our incredible matched donors, community fundraisers, corporate sponsors and everyone who made a donation, liked or shared our social media posts, or championed our cause.

This amazing result is evidence of the power of our army! We can't wait to see what our Holckner Family CF Impact grant will uncover in 2022 thanks to the donations from D-Day.

DONATION DAY ★ DECEMBER 3



OUR CORE VALUES

COLLABORATION

**WE FORM A DEEP
CONNECTION WITH OUR
SUPPORTERS TO BUILD A
RESILIENT COMMUNITY OF
LIKE-MINDED GO-GETTERS
- FOR WHOM WE ARE
FOREVER GRATEFUL.**

OUR PARTNERS

TOGETHER, WE CAN MAKE GREAT CHANGE HAPPEN. THANK YOU TO ALL OUR INCREDIBLE PARTNERS.



HOLCKNER FAMILY

We welcomed the Holckner Family as Naming Rights Partner of the annual *Cure4CF Holckner Family Impact Grant* for the next 3 years. Their support means we can increase the volume of research we fund each year and help accelerate a cure.

CMV GROUP FOUNDATION

The CMV Group Foundation is naming rights sponsor of our Community Ambassador Program. Through this innovative program we work with local, passionate and committed volunteers who represent Cure4CF in communities across Australia. The program helps increase our national reach and awareness by inspiring giving, activating partnerships and sharing the impact of our work.

AHA SA

AHA SA are partners once again through their *Pubs With Heart* program. Their support enabled Cure4CF to implement a digital innovation project, which saw Cure4CF upgrade their technology.

CYSTIC FIBROSIS SA (CFSA)

Via the fundraising efforts of the *65 Roses At Home* team, CFSA joined forces with Cure4CF this year to support our cure focused research program.

NATION

Since 2017 NATION Creative has provided pro-bono marketing and advertising services and support to Cure4CF. Their ongoing commitment to building capacity within the Foundation, development of the Cure4CF brand and belief in our work is priceless. Nation demonstrates what corporate social responsibility is all about. A perfect example of *All 4 The Fight*.

AIR DIFFUSION AGENCIES

Air Diffusion Agencies CEO and founders Bill & Rhonda Threadgold joined our *Heroes League* this year. Bill is a big believer in supporting the local economy and does this not just through providing jobs for South Australians but through Air Diffusion Agencies generous financial sponsorship of a huge range of sports clubs and organisations, community groups and charities.

BEYOND BANK FOUNDATION

Beyond Bank continue to offer innovative ways for our CF community to support our cause and raise funds for research. Their Community Rewards Accounts program once again generated essential funds for cystic fibrosis research.

JOIN THE FIGHT

WE'RE UNITING AN ARMY TO DEFEAT CYSTIC FIBROSIS AND BECAUSE OF OUR COMMUNITY, WE'RE DESTINED TO WIN.

MAKE A DONATION

Your gift, of whatever you can afford, will make a real difference. Donate online at cure4cf.org.

FUNDRAISE FOR US

Celebrating a birthday? Why not ask friends and family to donate to Cure4CF in lieu of a gift? Or pick a challenge and start fundraising for a cure, we have lots of options. Register at cure4cf.org

HOST AN EVENT FOR US

Got a great idea to raise funds for CF research? Why not host a fundraising event for us and we'll provide you with the tools you need to ensure it's a great success? Sign up at cure4cf.org.

BECOME A REGULAR DONOR

Become a part of the army who regularly donate weekly, monthly or annually and join the CF Fight Club. As little as \$5 each month can make a big difference to research we support. Sign up at cure4cf.org

JOIN THE HEROES LEAGUE

Our Heroes League plays a vital role in our pathway towards a cure. A high impact collective of giving, the Cure4CF Heroes League is made up of members who want to affect change by making a major annual contribution to the research we fund.

BECOME A CORPORATE PARTNER

Our corporate partners contribute their time, energy, skills and funds to bring us closer to a cure. We have many options from sponsorship or cause related marketing to workplace giving. A partnership with Cure4CF will have an impact.

OPEN A COMMUNITY REWARDS ACCOUNT

Open a Community Rewards Account with Beyond Bank. The more you save, the more interest you earn and the more money Beyond Bank will donate to C4CF, at no cost to you. Find out more at beyondbank.com.au/community-banking.

REMEMBER US IN YOUR WILL

Leave a lasting legacy through investment in research by leaving a gift to Cure4 Cystic Fibrosis in your will. Contact our friendly staff for more information at info@cure4cf.org

ADVOCATE FOR US

Use your social profile to help us raise awareness about the need for a cure for cystic fibrosis by liking, commenting and sharing our posts. We believe that a world without CF is within our reach and that research is the answer. If you believe this too, join us in our fight.

ACKNOWLEDGEMENTS

CURE4 CYSTIC FIBROSIS WOULD LIKE TO THANK AND ACKNOWLEDGE ALL THE DONORS, COMMUNITY FUNDRAISERS, PARTNERS, TRUSTS AND FOUNDATIONS WHO HAVE SUPPORTED OUR CAUSE IN 2021. OUR ARMY IS TOO BIG TO LIST EVERYONE INDIVIDUALLY NOW, HOWEVER WE HOPE YOU KNOW HOW VERY GRATEFUL WE ARE.

MAJOR CONTRIBUTORS

A CLAY	I STATHAM	P & F THORNBORROW
A ROBERTSON	J PEARSON	P & K MACHELL
BEYOND BANK AUS FOUNDATION	JA KOZLOWSKI	P HERRIMAN
B THREADGOLD	J DIKIH	R ABDIN
BORDER CF INC.	JE KOZLOWSKI	R PENFOLD-RUSSELL
BOTANIC MEDICAL	J BUCKLEY	R CLAYTON
BUDWORTH PTY LTD	J & P BLACK	R PETERSEN
CF GOULBURN & DISTRICT	J CLOSE	R THOMAS
C STEVENSON	JL KOCH	R MENZIES
CHARITY & FUN	J SACH	R CROSSLEY
CMV GROUP FOUNDATION	J STEVENSON	R PESSAROSSI
COLLIERS INTERNATIONAL	K SMITH	R LYNTON
COUNT CHARITABLE FOUNDATION	K & C ROBINS	S MURRAY
CF GEELONG FUNDRAISING EVENTS GROUP	K & G GRANT	S FREEMAN
CYSTIC FIBROSIS SA	L MONFRIES	S BARNETT
D&P MCKEE	L KOZLOWSKI	S DIMALINE
E MONEY	M JOHNSON	S MERLEHAN
ENCORE TISSUE	M & K STEELE	65K'S FOR CF GROUP
FLUID BUILDING APPROVALS	M DOHERTY	S MORRIS
G THOMAS	M O'NEILL	S SCOTT
G KNAGGE	M TREMUL	S ZADOW
G STEVENSON	MEDIBANK PRIVATE LIMITED	T MULLIGAN
H & I STATHAM	MELBOURNE FUTSAL	T STEWART
HAMMERTIME KITCHENS	M & R PROCTOR	W HARVEY
HOLCKNER FAMILY	N COOKE	W BOYCE
I & P WALL	O WOOD	W BURTON LEOPRDI

OUR CORE VALUES

PASSION

**OUR HEARTS, OUR HEADS,
OUR TALENTS AND OUR
TIME ARE ALL FOR THE
FIGHT.**

FINANCIAL STATEMENTS

CURE4CF ENGAGES THE SERVICES OF THINK ADVISORY TO CONDUCT ITS ANNUAL INTERNAL AUDIT AND PREPARE THESE AUDITED FINANCIAL STATEMENTS.

CURE4CF FOUNDATION LIMITED

ABN: 71136956137

**Financial Report For The Year Ended
31 December 2021**

Cure4CF Foundation Limited

ABN: 71136956137

Financial Report For The Year Ended 31 December 2021

CONTENTS	Page
Directors' Report	1
Auditor's Independence Declaration	3
Statement of Profit or Loss and Other Comprehensive Income	4
Statement of Financial Position	5
Statement of Changes in Equity	6
Statement of Cash Flows	7
Notes to the Financial Statements	8
Directors' Declaration	16
Independent Auditor's Report	17

CURE4CF FOUNDATION LIMITED
ABN: 71136956137
DIRECTORS' REPORT

Your directors present this report on the company for the financial year ended 31 December 2021.

Directors

The names of each person who has been a director during the year and to the date of this report are:

Lachlan Grey Monfries
Joanna Kate Close
Gregory Colin Savage
Clinton Jury
Kayi Li
Stephanie Morris
Jenna Dikih
Matthew Chong appointed (19/10/2021)
Phil Kearney appointed (19/10/2021)
Steve Zaddow appointed (19/10/2021)

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

Principal Activities

The principal activity of the company during the financial year was:

Cure4CF Foundation's principal activity during the financial year was the raising of funds to support raising awareness of cystic fibrosis airway disease and research into the development of a cure.

Information on Directors

Lachlan Grey Monfries	—	Director
Qualifications	—	BCom, MBA
Special Responsibilities	—	Chairperson
Joanna Kate Close	—	Director
Qualifications	—	BBiotech (Hons), FLGF, GAICD
Gregory Colin Savage	—	Director
Qualifications	—	BCom, GradDipBusAdm
Clinton Jury	—	Director
Qualifications	—	GAICD
Kayi Li	—	Director
Qualifications	—	CA, GAICD, MBA, BCom
Stephanie Morris	—	Director
Qualifications	—	GAICD, MBA, BBus, DipBioMedSci
Jenna Dikih	—	Director
Qualifications	—	BLaws (Hons), BCom, CA, GDLP
Matthew Chong	—	Director
Qualifications	—	BBioTech (Hons 1), PhD, GradCertAppFin
Phil Kearney	—	Director
Qualifications	—	PhD, MBA, CEO
Steve Zaddow	—	Director
Qualifications	—	MBBS (Hons), FRANZCR

CURE4CF FOUNDATION LIMITED
ABN: 71136956137
DIRECTORS' REPORT

Meetings of Directors

During the financial year, six meetings of directors were held. Attendances by each director were as follows:


	Directors' Meetings	
	Number eligible to attend	Number attended
Lachlan Grey Monfries	6	6
Joanna Kate Close	6	6
Gregory Colin Savage	6	5
Clinton Jury	6	5
Kayi Li	1	-
Stephanie Morris	6	4
Jenna Dikih	6	6
Matthew Chong	2	2
Phil Kearney	2	2
Steve Zaddow	2	2

The company is incorporated under the Corporations Act 2001 and is a company limited by guarantee. If the company is wound up, the constitution states that each member is required to contribute a maximum of \$10 each towards meeting any outstanding obligations of the company. At 31 December 2021, the total amount that members of the company are liable to contribute if the company is wound up is \$100 (2020: \$70).

Auditor's Independence Declaration

The lead auditor's independence declaration for the year ended 31 December 2021 has been received and can be found on page 3 of the financial report.

This directors' report is signed in accordance with a resolution of the Board of Directors.

Director 

Lachlan Grey Monfries

Dated this 12th day of April 2022

CURE4CF FOUNDATION LIMITED
ABN: 71136956137
AUDITOR'S INDEPENDENCE DECLARATION UNDER S 307C OF
THE CORPORATIONS ACT 2001 TO THE DIRECTORS OF CURE4CF FOUNDATION LIMITED

I declare that, to the best of my knowledge and belief, during the year ended 31 December 2021 there have been no contraventions of:

- (i) the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- (ii) any applicable code of professional conduct in relation to the audit.

Name of Firm Thnk Advisory



Name of Partner Adam Drabsch

Date 30/03/2022

Address 1 Alexandra Avenue, Rose Park, SA 5067

CURE4CF FOUNDATION LIMITED

ABN: 71136956137

**STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR
ENDED 31 DECEMBER 2021**

	Note	2021	2020
		\$	\$
Revenue	2	889,229	415,651
Other income	2	2,592	67,136
Employee benefits expense		(166,790)	(163,628)
Audit, legal and consultancy fees		(20,163)	(7,853)
Marketing expenses		(35,059)	(14,175)
Administration expenses		(25,418)	(5,902)
Interest and financial expenses		(1,596)	(1,249)
Grant expenditure		(374,734)	6,027
Travel and Board expenses		(1,345)	(2,183)
IT expenses		(1,972)	(3,115)
Current year surplus/(deficit) before income tax		<u>264,744</u>	<u>290,710</u>
Income tax expense		<u>-</u>	<u>-</u>
Net current year surplus/(deficit)		<u><u>264,744</u></u>	<u><u>290,710</u></u>
Other comprehensive income			
Total other comprehensive (losses)/income for the year		<u>-</u>	<u>-</u>
Total comprehensive income for the year		<u><u>264,744</u></u>	<u><u>290,710</u></u>
Profit/(loss) attributable to members of the entity		<u>264,744</u>	<u>290,710</u>
Total comprehensive income attributable to members of the entity		<u><u>264,744</u></u>	<u><u>290,710</u></u>

The accompanying notes form part of these financial statements.

CURE4CF FOUNDATION LIMITED
ABN: 71136956137
STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2021

	Note	2021 \$	2020 \$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	3	1,118,405	690,171
Other current assets	4	101,591	268,056
TOTAL CURRENT ASSETS		<u>1,219,996</u>	<u>958,227</u>
TOTAL ASSETS		<u>1,219,996</u>	<u>958,227</u>
LIABILITIES			
CURRENT LIABILITIES			
Accounts payable and other payables	5	4,515	8,031
Employee provisions	6	10,396	9,855
TOTAL CURRENT LIABILITIES		<u>14,911</u>	<u>17,886</u>
TOTAL LIABILITIES		<u>14,911</u>	<u>17,886</u>
NET ASSETS		<u>1,205,085</u>	<u>940,341</u>
EQUITY			
Retained surplus		1,205,085	940,341
TOTAL EQUITY		<u>1,205,085</u>	<u>940,341</u>

The accompanying notes form part of these financial statements.

CURE4CF FOUNDATION LIMITED
ABN: 71136956137
STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER
2021

	Note	Retained Surplus \$	Total \$
Balance at 1 January 2020		649,177	649,177
Comprehensive Income			
Surplus / (deficit) for the year attributable to members of the entity		290,710	290,710
Other comprehensive income for the year			
Adjustment to retained earnings		454	454
Total other comprehensive income		454	454
Total comprehensive income attributable to members of the entity		291,164	291,164
Balance at 31 December 2020		940,341	940,341
Balance at 1 January 2021		940,341	940,341
Comprehensive Income			
Surplus / (deficit) for the year attributable to members of the entity		264,744	264,744
Total comprehensive income attributable to members of the entity		264,744	264,744
Balance at 31 December 2021		1,205,085	1,205,085

The accompanying notes form part of these financial statements:

CURE4CF FOUNDATION LIMITED
ABN: 71136956137
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2021

	Note	2021 \$	2020 \$
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from donations, bequests and grants		928,933	440,414
Payments to suppliers, employees and grantees		(503,291)	(404,773)
Interest received		2,592	2,372
Interest paid		-	(1,249)
Net cash generated from operating activities	8	428,234	36,764
Net increase in cash held		428,234	36,764
Cash on hand at beginning of the financial year		690,171	653,407
Cash on hand at end of the financial year	3	1,118,405	690,171

The accompanying notes form part of these financial statements.

CURE4CF FOUNDATION LIMITED
ABN: 71136956137
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

Note 1 Summary of Significant Accounting Policies

The directors have prepared the financial statements on the basis that the company is a non-reporting entity because there are no users dependent on general purpose financial statements. These financial statements are therefore special purpose financial statements that have been prepared in order to meet the requirements of the Corporations Act 2001. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

The financial statements have been prepared in accordance with the mandatory Australian Accounting Standards applicable to entities reporting under the Corporations Act 2001 and the significant accounting policies disclosed below, which the directors have determined are appropriate to meet the needs of members. Such accounting policies are consistent with those of previous periods unless stated otherwise.

The financial statements, except for the cash flow information, have been prepared on an accrual basis and are based on historical costs unless otherwise stated in the notes. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise. The amounts presented in the financial statements have been rounded to the nearest dollar.

Basis of Preparation

Cure4CF Foundation Limited applies Australian Accounting Standards – Reduced Disclosure Requirements as set out in AASB 1053: Application of Tiers of Australian Accounting Standards.

The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards – Reduced Disclosure Requirements of the Australian Accounting Standards Board (AASB) and the Australian Charities and Not-for-profits Commission Act 2012. The company is a not-for-profit entity for financial reporting purposes under Australian Accounting Standards.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in financial statements containing relevant and reliable information about transactions, events and conditions. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless otherwise stated.

The financial statements were authorised for issue on 12th April 2022 by the directors of the company.

Accounting Policies

(a) Revenue

Non-reciprocal grant revenue is recognised in profit or loss when the company obtains control of the grant and it is probable that the economic benefits gained from the grant will flow to the company and the amount of the grant can be measured reliably.

If conditions are attached to the grant which must be satisfied before it is eligible to receive the contribution, the recognition of the grant as revenue will be deferred until those conditions are satisfied.

When grant revenue is received whereby the company incurs an obligation to deliver economic value directly back to the contributor, this is considered a reciprocal transaction and the grant revenue is recognised in the statement of financial position as a liability until the service has been delivered to the contributor, otherwise the grant is recognised as income on receipt.

Cure4CF Foundation Limited receives non-reciprocal contributions for zero or a nominal value. These assets are recognised at fair value on the date of acquisition in the statement of financial position, with a corresponding amount of income recognised in profit or loss.

Donations and bequests are recognised as revenue when received.

Interest revenue is recognised using the effective interest method, which for floating rate financial assets is the rate inherent in the instrument. Dividend revenue is recognised when the right to receive a dividend has been established.

Revenue from the rendering of a service is recognised upon the delivery of the service to the customers.

All revenue is stated net of the amount of goods and services tax.

(b) Inventories

Inventories held for sale are measured at the lower of cost and net realisable value. Inventories held for distribution are measured at cost adjusted, when applicable, for any loss of service potential.

Inventories acquired at no cost, or for nominal consideration, are valued at the current replacement cost as at the date of acquisition.

CURE4CF FOUNDATION LIMITED

ABN: 71136956137

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

(c) Leases

The Company as lessee

At inception of a contract, the company assesses if the contract contains or is a lease. If there is a lease present, a right-of-use asset and a corresponding lease liability is recognised by the company where the company is a lessee. However, all contracts that are classified as short-term leases (ie a lease with a remaining lease term of 12 months or less) and leases of low-value assets are recognised as an operating expense on a straight-line basis over the term of the lease.

Initially, the lease liability is measured at the present value of the lease payments still to be paid at commencement date. The lease payments are discounted at the interest rate implicit in the lease. If this rate cannot be readily determined, the company uses the incremental borrowing rate.

Lease payments included in the measurement of the lease liability are as follows:

- fixed lease payments less any lease incentives;
- variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date;
- the amount expected to be payable by the lessee under residual value guarantees;
- the exercise price of purchase options, if the lessee is reasonably certain to exercise the options;
- lease payments under extension options if lessee is reasonably certain to exercise the options; and
- payments of penalties for terminating the lease, if the lease term reflects the exercise of an option to terminate the lease

The right-of-use assets comprise the initial measurement of the corresponding lease liability as mentioned above, any lease payments made at or before the commencement date as well as any initial direct costs. The subsequent measurement of the right-of-use assets is at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated over the lease term or useful life of the underlying asset whichever is the shortest.

Where a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the company anticipates to exercise a purchase option, the specific asset is depreciated over the useful life of the underlying asset.

Concessionary Leases

For leases that have significantly below-market terms and conditions principally to enable the company to further its objectives (commonly known as peppercorn/concessionary leases), the company has adopted the temporary relief under AASB 16 and measures the right-of-use assets at cost on initial recognition.

(d) Financial Instruments

Initial Recognition and Measurement

Financial assets and financial liabilities are recognised when the company becomes a party to the contractual provisions to the instrument. For financial assets, this is equivalent to the date that the company commits itself to either purchase or sell the asset (i.e. trade date accounting is adopted).

Financial instruments are initially measured at fair value plus transactions costs except where the instrument is classified 'at fair value through profit or loss' in which case transaction costs are recognised immediately as expenses in profit or loss.

Classification and Subsequent Measurement

Financial instruments are subsequently measured at fair value (refer to Note 1(n)), amortised cost using the effective interest method, or cost.

Amortised cost is calculated as the amount at which the financial asset or financial liability is measured at initial recognition less principal repayments and any reduction for impairment, and adjusted for any cumulative amortisation of the difference between that initial amount and the maturity amount calculated using the effective interest method.

The *effective interest method* is used to allocate interest income or interest expense over the relevant period and is equivalent to the rate that exactly discounts estimated future cash payments or receipts (including fees, transaction costs and other premiums or discounts) through the expected life (or when this cannot be reliably predicted, the contractual term) of the financial instrument to the net carrying amount of the financial asset or financial liability. Revisions to expected future net cash flows will necessitate an adjustment to the carrying amount with a consequential recognition of an income or expense item in profit or loss.

CURE4CF FOUNDATION LIMITED
ABN: 71136956137
NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

(i) Financial assets at fair value through profit or loss

Financial assets are classified at "fair value through profit or loss" when they are held for trading for the purpose of short-term profit taking, derivatives not held for hedging purposes, or when they are designated as such to avoid an accounting mismatch or to enable performance evaluation where a group of financial assets is managed by key management personnel on a fair value basis in accordance with a documented risk management or investment strategy. Such assets are subsequently measured at fair value with changes in carrying amount being included in profit or loss.

(ii) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are subsequently measured at amortised cost. Gains or losses are recognised in profit or loss through the amortisation process and when the financial asset is derecognised.

(iii) Held-to-maturity investments

Held-to-maturity investments are non-derivative financial assets that have fixed maturities and fixed or determinable payments, and it is the company's intention to hold these investments to maturity. They are subsequently measured at amortised cost. Gains or losses are recognised in profit or loss through the amortisation process and when the financial asset is derecognised.

(iv) Available-for-sale investments

Available-for-sale investments are non-derivative financial assets that are either not capable of being classified into other categories of financial assets due to their nature or they are designated as such by management. They comprise investments in the equity of other entities where there is neither a fixed maturity nor fixed or determinable payments.

They are subsequently measured at fair value with any remeasurements other than impairment losses and foreign exchange gains and losses recognised in other comprehensive income. When the financial asset is derecognised, the cumulative gain or loss pertaining to that asset previously recognised in other comprehensive income is reclassified into profit or loss.

Available-for-sale financial assets are classified as non-current assets when they are expected to be sold within 12 months after the end of the reporting period. All other available-for-sale financial assets are classified as current assets.

(v) Financial liabilities

Non-derivative financial liabilities other than financial guarantees are subsequently measured at amortised cost. Gains or losses are recognised in profit or loss through the amortisation process and when the financial liability is derecognised.

Impairment

At the end of each reporting period, the company assesses whether there is objective evidence that a financial asset has been impaired. A financial asset (or a group of financial assets) is deemed to be impaired if, and only if, there is objective evidence of impairment as a result of one or more events (a "loss event") having occurred, which has an impact on the estimated future cash flows of the financial asset(s).

In the case of available-for-sale financial assets, a significant or prolonged decline in the market value of the instrument is considered to constitute a loss event. Impairment losses are recognised in profit or loss immediately. Also, any cumulative decline in fair value previously recognised in other comprehensive income is reclassified to profit or loss at this point.

In the case of financial assets carried at amortised cost, loss events may include: indications that the debtors or a group of debtors are experiencing significant financial difficulty, default or delinquency in interest or principal payments; indications that they will enter bankruptcy or other financial reorganisation; and changes in arrears or economic conditions that correlate with defaults.

For financial assets carried at amortised cost (including loans and receivables), a separate allowance account is used to reduce the carrying amount of financial assets impaired by credit losses. After having taken all possible measures of recovery, if management establishes that the carrying amount cannot be recovered by any means, at that point the written-off amounts are charged to the allowance account or the carrying amount of impaired financial assets is reduced directly if no impairment amount was previously recognised in the allowance accounts.

CURE4CF FOUNDATION LIMITED

ABN: 71136956137

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

When the terms of financial assets that would otherwise have been past due or impaired have been renegotiated, the company recognises the impairment for such financial assets by taking into account the original terms as if the terms have not been renegotiated so that the loss events that have occurred are duly considered.

Derecognition

Financial assets are derecognised where the contractual rights to receipt of cash flows expire or the asset is transferred to another party whereby the company no longer has any significant continuing involvement in the risks and benefits associated with the asset. Financial liabilities are derecognised when the related obligations are discharged, cancelled or have expired. The difference between the carrying amount of the financial liability, which is extinguished or transferred to another party, and the fair value of consideration paid, including the transfer of non-cash assets or liabilities assumed, is recognised in profit or loss.

(e) Impairment of Assets

At the end of each reporting period, the company assesses whether there is any indication that an asset may be impaired. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset's fair value less costs of disposal and value in use, to the asset's carrying amount. Any excess of the asset's carrying amount over its recoverable amount is recognised immediately in profit or loss, unless the asset is carried at a revalued amount in accordance with another Standard (e.g. in accordance with the revaluation model in AASB 116). Any impairment loss of a revalued asset is treated as a revaluation decrease in accordance with that other Standard.

Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Impairment testing is performed annually for goodwill and intangible assets with indefinite lives.

(f) Employee Benefits

Short-term employee benefits

Provision is made for the Company's obligation for short-term employee benefits. Short-term employee benefits are benefits (other than termination benefits) that are expected to be settled wholly within 12 months after the end of the annual reporting period in which the employees render the related service, including wages, salaries and sick leave. Short-term employee benefits are measured at the (undiscounted) amounts expected to be paid when the obligation is settled.

The company's obligations for short-term employee benefits such as wages, salaries and sick leave are recognised as part of current trade and other payables in the statement of financial position.

Other long-term employee benefits

The company classifies employees' long service leave and annual leave entitlements as other long-term employee benefits as they are not expected to be settled wholly within 12 months after the end of the annual reporting period in which the employees render the related service. Provision is made for the company's obligation for other long-term employee benefits, which are measured at the present value of the expected future payments to be made to employees. Expected future payments incorporate anticipated future wage and salary levels, durations of service and employee departures, and are discounted at rates determined by reference to market yields at the end of the reporting period on government bonds that have maturity dates that approximate the terms of the obligations. Upon the remeasurement of obligations for other long-term employee benefits, the net change in the obligation is recognised in profit or loss classified under employee benefits expense.

The Company's obligations for long-term employee benefits are presented as non-current liabilities in its statement of financial position, except where the Company does not have an unconditional right to defer settlement for at least twelve months after the reporting date, in which case the obligations are presented as current liabilities.

(g) Cash and Cash Equivalents

Cash and cash equivalents include cash on hand, deposits held at-call with banks, other short-term highly liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within short-term borrowings in current liabilities on the statement of financial position.

(h) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO).

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the ATO is included with other receivables or payables in the statement of financial position.

CURE4CF FOUNDATION LIMITED

ABN: 71136956137

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to, the ATO are presented as operating cash flows included in receipts from customers or payments to suppliers.

(i) Income Tax

No provision for income tax has been raised as the company is exempt from income tax under Div 50 of the *Income Tax Assessment Act 1997*.

(j) Provisions

Provisions are recognised when the company has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured. Provisions recognised represent the best estimate of the amounts required to settle the obligation at the end of reporting period.

(k) Comparative Figures

When required by Accounting Standards comparative figures have been adjusted to conform to changes in presentation for the current financial year.

(l) Trade and Other Payables

Trade and other payables represent the liabilities for goods and services received by the company during the reporting period that remain unpaid at the end of the reporting period. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

(m) Critical Accounting Estimates and Judgements

The directors evaluate estimates and judgements incorporated into the financial statements based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company.

There are no critical accounting estimates or judgements required.

(n) Fair Value of Assets and Liabilities

The company measures some of its assets and liabilities at fair value on either a recurring or non-recurring basis, depending on the requirements of the applicable Accounting Standard.

"Fair value" is the price the company would receive to sell an asset or would have to pay to transfer a liability in an orderly (ie unforced) transaction between independent, knowledgeable and willing market participants at the measurement date.

As fair value is a market-based measure, the closest equivalent observable market pricing information is used to determine fair value. Adjustments to market values may be made having regard to the characteristics of the specific asset or liability. The fair values of assets and liabilities that are not traded in an active market are determined using one or more valuation techniques. These valuation techniques maximise, to the extent possible, the use of observable market data.

To the extent possible, market information is extracted from the principal market for the asset or liability (ie the market with the greatest volume and level of activity for the asset or liability). In the absence of such a market, market information is extracted from the most advantageous market available to the company at the end of the reporting period (ie the market that maximises the receipts from the sale of the asset or minimises the payments made to transfer the liability, after taking into account transaction costs and transport costs).

For non-financial assets, the fair value measurement also takes into account a market participant's ability to use the asset in its highest and best use or to sell it to another market participant that would use the asset in its highest and best use.

The fair value of liabilities and the company's own equity instruments (if any) may be valued, where there is no observable market price in relation to the transfer of such financial instrument, by reference to observable market information where such instruments are held as assets. Where this information is not available, other valuation techniques are adopted and where significant, are detailed in the respective note to the financial statements.

CURE4CF FOUNDATION LIMITED

ABN: 71136956137

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

Note 2 Revenue and Other Income

	2021 \$	2020 \$
Revenue		
Revenue from continuing operations		
— Appeals	53,669	42,613
— Bequests	320,000	-
— Heroes League (Formerly Ambassador's Circle)	69,600	36,000
— Community fundraising	84,164	75,354
— Community reward accounts	5,980	8,191
— Corporate donations	32,623	61,787
— Donation tap point machines	1,491	277
— General donations - solicited	-	1,218
— General donations - unsolicited	18,747	2,181
— Major gifts	100,000	80,000
— Peer 2 peer	70,281	19,473
— Personal campaigns	7,114	6,112
— Regular giving income	15,817	18,029
— Trusts and foundations	106,917	62,017
— Wine sales	-	120
— Workplace giving	2,826	2,281
Total revenue	<u>889,229</u>	<u>415,651</u>
Other income		
— Cashflow boost	-	25,764
— Jobkeeper	-	39,000
— Interest income	2,592	2,372
Total other income	<u>2,592</u>	<u>67,136</u>
Total revenue and other income	<u><u>891,821</u></u>	<u><u>482,788</u></u>

Note 3 Cash and Cash Equivalents

	2021 \$	2020 \$
CURRENT		
Cash at bank	1,118,405	690,171
Cash on hand	-	-
	<u>1,118,405</u>	<u>690,171</u>

Note 4 Other Assets

	2021 \$	2020 \$
Grant monies refundable (NFMRI)	-	40,000
Prepayments	101,293	228,056
Accounts receivable	298	-
	<u>101,591</u>	<u>268,056</u>

Note 5 Trade and Other Payables

	2021 \$	2020 \$
CURRENT		
Accounts payable	1,509	4,595
PAYG withholding (receivable) / payable	4,622	2,724
Other current payables	1,760	2,984
GST (receivable) / payable	(3,376)	(2,272)
Note	<u>5(a)</u>	<u>8,031</u>

CURE4CF FOUNDATION LIMITED

ABN: 71136956137

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

		2021 \$	2020 \$
(a) Financial liabilities at amortised cost classified as accounts payable and other payables			
Accounts payable and other payables:			
— Total current		4,515	8,031
		<u>4,515</u>	<u>8,031</u>
Less deferred income		-	-
Financial liabilities as accounts payable and other payables	9	<u>4,515</u>	<u>8,031</u>

Note 6 Provisions

	2021 \$	2020 \$
CURRENT		
Provision for employee benefits: annual leave	10,396	9,855
Provision for employee benefits: long service leave	-	-
	<u>10,396</u>	<u>9,855</u>
NON-CURRENT		
Provision for employee benefits: long service leave	-	-
	<u>10,396</u>	<u>9,855</u>

Employee Provisions

Employee provisions represents amounts accrued for annual leave and long service leave.

The current portion for this provision includes the total amount accrued for annual leave entitlements and the amounts accrued for long service leave entitlements that have vested due to employees having completed the required period of service. Based on past experience, the company does not expect the full amount of annual leave or long service leave balances classified as current liabilities to be settled within the next 12 months. However, these amounts must be classified as current liabilities since the company does not have an unconditional right to defer the settlement of these amounts in the event employees wish to use their leave entitlement.

The non-current portion for this provision includes amounts accrued for long service leave entitlements that have not yet vested in relation to those employees who have not yet completed the required period of service.

In calculating the present value of future cash flows in respect of long service leave, the probability of long service leave being taken is based upon historical data. The measurement and recognition criteria for employee benefits have been discussed in Note 1(f).

Note 7 Events After the Reporting Period

The directors are not aware of any significant events since the end of the reporting period.

Note 8 Cash Flow Information

	2021 \$	2020 \$
Reconciliation of Cash Flows from Operating Activities with Net Current Year Surplus		
Net current year surplus	264,744	290,710
Adjustment for:		
Retained earnings adjustment	-	454
Movement in working capital changes:		
Increase/(decrease) in accounts payable and other payables	(3,516)	15,996
Increase/(decrease) in employee provisions	541	(2,340)
(Increase)/decrease in other assets	166,465	(268,056)
	<u>428,234</u>	<u>10,800</u>

Note 9 Financial Risk Management

The company's financial instruments consist mainly of deposits with banks, local money market instruments, short-term and long-term investments, receivables and payables, and lease liabilities.

The carrying amounts for each category of financial instruments, measured in accordance with AASB 139 as detailed in the accounting policies to these financial statements, are as follows:

CURE4CF FOUNDATION LIMITED

ABN: 71136956137

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

	Note	2021 \$	2020 \$
Financial assets			
Cash and cash equivalents	3	1,118,405	690,171
Total financial assets		<u>1,118,405</u>	<u>690,171</u>
Financial liabilities			
Financial liabilities at amortised cost:			
— accounts payable and other payables	5(a)	4,515	8,031
Total financial liabilities		<u>4,515</u>	<u>8,031</u>

Note 10 Key Management Personnel Compensation

Key Management Personnel

Any person(s) having authority and responsibility for planning, directing and controlling the activities of the company directly or indirectly, including any director (whether executive or otherwise) is considered key management personnel (KMP). The Executive Manager along with Directors are considered key management personnel. Directors receive nil remuneration.

The totals of remuneration paid to KMP of the company during the year are as follows:

	2021 \$	2020 \$
KMP compensation:		
— short-term employee benefits	86,343	95,236
— post-employment benefits	8,179	9,047
— other long-term benefits	-	-
	<u>94,522</u>	<u>104,283</u>

Note 11 Related Party Transactions

The Company's related parties include its key management personnel and related entities. Unless otherwise stated, none of the transactions incorporate special terms and conditions and no guarantees were given or received.

There were no related party transactions within the year ended 31 December 2021 (2020: nil).

Note 12 Entity Details

The registered office of the entity is:

Cure4CF Foundation Limited
PO Box 313 Greenwith SA 5125

The principal place of business is:

Cure4CF Foundation Limited
PO Box 313 Greenwith SA 5125

Note 13 Members' Guarantee

The company is incorporated under the Corporations Act 2001 and is a company limited by guarantee. If the company is wound up, the constitution states that each member is required to contribute a maximum of \$10 towards meeting any outstanding obligations of the company. At 31 December 2021 the number of members was 10 (2020: 7).

CURE4CF FOUNDATION LIMITED
ABN: 71136956137
DIRECTORS' DECLARATION

In accordance with a resolution of the directors of Cure4CF Foundation Limited, the directors declare that:

1. The financial statements and notes, as set out on pages 4 to 15, are in accordance with the Australian Charities and Not-for-profits Commission Act 2012 and:
 - (a) comply with Australian Accounting Standards - Reduced Disclosure Requirements; and
 - (b) give a true and fair view of the financial position of the registered entity as at 31 December 2021 and of its performance for the year ended on that date.
2. There are reasonable grounds to believe that the registered entity will be able to pay its debts as and when they become due and payable.

This declaration is signed in accordance with subs 60.15(2) of the Australian Charities and Not-for-profits Commission Regulation 2013.

Director 

Lachlan Grey Monfries

Dated this 12th day of April 2022